PDS Biotechnology Corp

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

PDSB$1.03-4.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Common Stock · Additional
	Shares Issued	Amount	Paid-in Capital	Accumulated Deficit	Total Equity
January 1, 2024	33,094,521	$10,921	$170,620,641	$(144,500,615)	$26,130,947
Stock-based compensation expense	-	-	1,630,011	-	1,630,011
Issuances of common stock from the Sales Agreement, net	3,428,681	1,131	19,493,342	-	19,494,473
Issuances of common stock, from exercise of stock options	156,073	52	531,039	-	531,091
Net loss	-	-	-	(10,603,477)	(10,603,477)
Balance - March 31, 2024	36,679,275	$12,104	$192,275,033	$(155,104,092)	$37,183,045
Stock-based compensation expense	-	-	1,795,722	-	1,795,722
Issuance of common stock for consulting agreement	100,000	33	266,967	-	267,000
Net loss	-	-	-	(8,327,897)	(8,327,897)
Balance - June 30, 2024	36,779,275	$12,137	$194,337,722	$(163,431,989)	$30,917,870
Stock-based compensation expense	-	-	1,778,272	-	1,778,272
Amortization of issuance costs related to the Sales Agreement	-	-	(67,179)	-	(67,179)
Issuances of common stock from exercise of stock options	40,535	13	98,487	-	98,500
Net loss	-	-	-	(10,726,658)	(10,726,658)
Balance - September 30, 2024	36,819,810	$12,150	$196,147,302	$(174,158,647)	$22,000,805

Common Stock · Additional
	Shares Issued	Amount	Paid-in Capital	Accumulated Deficit	Total Equity
January 1, 2025	37,987,380	$12,536	$201,103,311	$(182,110,999)	$19,004,848
Stock-based compensation expense	-	-	1,253,882	-	1,253,882
Issuance of common stock for consulting agreement	100,000	33	126,967	-	127,000
Issuance of common stock per vendor contract	50,000	17	76,484	-	76,501
Issuances of common stock from the Sales Agreement, net	205,350	68	306,047	-	306,115
Issuances of common stock, net of issuance costs	6,396,787	2,111	6,919,908	-	6,922,019
Issuance of pre-funded warrants	-	-	1,009,969	-	1,009,969
Issuance of warrants	-	-	2,150,771	-	2,150,771
Exercise of pre-funded warrants	706,334	233	(162)	-	71
Net loss	-	-	-	(8,488,967)	(8,488,967)
Balance - March 31, 2025	45,445,851	$14,998	$212,947,177	$(190,599,966)	$22,362,209
Stock-based compensation expense	-	-	448,029	-	448,029
Issuances of common stock from the Sales Agreement, net	960,511	317	1,460,325	-	1,460,642
Issuances of common stock, net of issuance costs	-	-	50,000	-	50,000
Issuance of warrants	-	-	1,073,089	-	1,073,089
Exercise of pre-funded warrants	227,000	75	(52)	-	23
Net loss	-	-	-	(9,434,208)	(9,434,208)
Balance - June 30, 2025	46,633,362	$15,390	$215,978,568	$(200,034,174)	$15,959,784
Stock-based compensation expense	-	-	1,246,485	-	1,246,485
Issuances of common stock from the Sales Agreement, net	1,072,080	354	1,256,298	-	1,256,652
Net loss	-	-	-	(9,009,411)	(9,009,411)
Balance - September 30, 2025	47,705,442	$15,744	$218,481,351	$(209,043,585)	$9,453,510

Index

Condensed Consolidated

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.